Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

被引：0
作者：
Claus-Henning Köhne
Meinolf Karthaus
Laurent Mineur
Josef Thaler
Marc Van den Eynde
Javier Gallego
Reija Koukakis
Marloes Berkhout
Ralf-Dieter Hofheinz
机构：
[1] Klinikum Oldenburg,Department of Oncology and Haematology
[2] Städtisches Klinikum München,Department of Hematology and Oncology
[3] Institut Sainte Catherine,Département de Cancérologie Digestive
[4] Klinikum Wels-Grieskirchen,Internal Medicine IV (Hematology and Medical Oncology)
[5] Cliniques Universitaires Saint-Luc UCL,Department of Gastroenterology and Medical Oncology, Institut Roi Albert II
[6] Hospital General Universitario de Elche,Servicio de Oncología Médica
[7] Amgen Ltd,Department of Biostatistics
[8] Amgen B.V.,Medical Development
[9] Tagestherapiezentrum,undefined
[10] Interdisziplinäres Tumorzentrum,undefined
[11] Universitätsmedizin Mannheim,undefined
来源：
Drugs in R&D | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 174 条
  • [1] Van Cutsem E(2016)ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Ann Oncol 27 1386-1422
  • [2] Cervantes A(2012)First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer J Cancer Res Clin Oncol 138 65-72
  • [3] Adam R(2016)Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer Br J Cancer 115 1215-1222
  • [4] Sobrero A(2017)On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis Cancer Chemother Pharmacol 79 275-285
  • [5] Van Krieken JH(2015)Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer Eur J Cancer 51 1231-1242
  • [6] Aderka D(2018)Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials Br J Cancer 119 303-312
  • [7] Kohne CH(2017)Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in 3 randomised panitumumab trials J Cancer Res Clin Oncol 144 321-335
  • [8] Hofheinz R(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
  • [9] Mineur L(2015)Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC) Eur J Cancer 51 1927-1936
  • [10] Letocha H(2016)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial Lancet Oncol 17 1426-1434
12345678910